This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (30)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Neurology  • Neuroendocrinology  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Michael Polydefkis, MD; John W. Griffin, MD; Justin McArthur, MBBS, MPH

JAMA. 2003;290:1371-1376.

Patients with complaints of numbness, tingling, and dysesthesias in the toes and feet are frequently referred to neurologists. Often, the only objective evidence for peripheral nerve dysfunction in these patients is limited to small-caliber sensory nerve fibers. On examination these patients may have reduced distal pinprick sensation, and distal leg skin biopsies show loss of small-caliber nerve fibers. Studies focusing on small-caliber nerve fibers have led to a growing impression that neuropathy can be associated with early diabetes or impaired glucose tolerance (IGT). Often, neuropathy can be the presenting symptom of either diabetes or IGT. Furthermore, the oral glucose tolerance test appears to be a more sensitive measure of glucose dysmetabolism in these patients than levels of fasting blood glucose or glycated hemoglobin. Patients with IGT-associated neuropathy may represent an attractive target population for future regenerative studies given that their neuropathy is less severe and presumably more easily reversed than neuropathy occurring in patients with diabetes.

Historically, small-caliber fibers have not been extensively evaluated due to a lack of objective measures. Several measures to evaluate these fibers are emerging, including skin biopsy with visualization of epidermal nerve fibers. The accessibility of epidermal nerve fibers makes them an attractive target for nerve injury models, which have potential for development as novel outcome measures. Such approaches may address some of the challenges of past diabetic polyneuropathy trials.

Author Affiliations: Departments of Neurology (Drs Polydefkis, Griffin, and McArthur), Pathology (Dr Griffin), Neuroscience (Dr Griffin), and Epidemiology (Dr McArthur), The Johns Hopkins Hospital, Baltimore, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reduced Vascular Endothelial Growth Factor Expression and Intra-Epidermal Nerve Fiber Loss in Human Diabetic Neuropathy
Quattrini et al.
Diabetes Care 2008;31:140-145.
ABSTRACT | FULL TEXT  

New perspectives on the management of diabetic peripheral neuropathic pain
Jensen et al.
Diabetes and Vascular Disease Research 2006;3:108-119.
ABSTRACT  

Diabetic Peripheral Neuropathic Pain: Clinical and Quality-of-Life Issues
Argoff et al.
Mayo Clin Proc. 2006;81:S3-S11.
ABSTRACT | FULL TEXT  

Clinical spectrum of cryoglobulinaemic neuropathy
Gemignani et al.
J. Neurol. Neurosurg. Psychiatry 2005;76:1410-1414.
ABSTRACT | FULL TEXT  

Morphine, Gabapentin, or Their Combination for Neuropathic Pain
Gilron et al.
NEJM 2005;352:1324-1334.
ABSTRACT | FULL TEXT  

Oxidative Stress in the Pathogenesis of Diabetic Neuropathy
Vincent et al.
Endocr. Rev. 2004;25:612-628.
ABSTRACT | FULL TEXT  

Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments
Shun et al.
Brain 2004;127:1593-1605.
ABSTRACT | FULL TEXT